Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Deferral from OTC labeling final reg for Suphedrine Cold & Cough Liquid-Filled Capsules and Day Time Liquid-Filled Capsules sought pending FDA response to private labeler's October 2000 exemption request to allow use of phrase "may contain" when listing inactives. "Due to the time needed to change labeling specifications, develop customer-specific art, obtain customer approval, print labeling components and label finished product, it is necessary that Perrigo initiate a labeling conversion now" to convert products by May 16, 2002 compliance date, firm says Aug. 9
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning